| Compound |
Anti-HIV in MT2 Cells |
Anti-HIV in Human PBMCs |
| 10% FBSa,b |
10% FBS + HSA + α1-AGPb |
100% HSd |
10% FBSa,c |
10% FBS + HSA + α1-AGPc |
| EC50 (nM) |
EC50 (nM) |
EC95 (nM)e |
EC50 (nM) |
EC95 (nM)e |
EC50 (nM) |
EC50 (nM) |
EC95 (nM)e |
| GS-9224 |
1.3 ±1.1 |
19 ±5 |
118 ±28 |
16 |
100 |
2.2 ±0.1 |
19 ±6 |
121 ±39 |
| GS-9160 |
1.2 ±0.5 |
13 ±6 |
76 ±35 |
12 |
75 |
1.2 ±0.9 |
13 ±13 |
80 ±79 |
| RAL |
7.5 ±1 |
23 ±5 |
162 ±35 |
– |
– |
2.6 ±1.2 |
19 ±14 |
121 ±93 |
|
aThe EC50 for Control (10% FBS) and (10% FBS + HSA + a1-AGP ) were run in parallel.
b Mean ±SD of at least 3 independent experiments.
c Mean ±SD of at least 3 donors.
d Mean of at least 2 independent experiments.
e The values of EC95 were calculated from EC50 |
| Table 2: Effect of Serum Proteins on the Antiviral Activity of GS-9224. |
